AUTO1
Phase 2Cell therapy
AUTO1 is one of 13 biologic programs targeting Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
14 competitors in Acute Lymphoblastic Leukaemia
#DrugCompanyPhaseTrials
1Cytoxan
BBaxter Healthcare Corporation
Phase 2
Mesnex
BBaxter Healthcare Corporation
Phase 2
Campath
GGenzyme, a Sanofi Company
Phase 2
Fludara
SanofiPhase 1
Tepadina
Jazz PharmaceuticalsPreclinical
AUTO1
AAutolus Limited
Phase 2
Busulfex
Akero TherapeuticsPreclinical
Noxafil
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Grafapex
MMedexus Pharma, Inc.
Preclinical
CAR-T Cell Therapy
TThe First Affiliated Hospital of Soochow University
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Acute Lymphoblastic Leukaemia1 trial
Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AUTO1. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Phase 2[1]
- Company
- AAutolus Limited